Lung Cancer Targeting Trend: Teresa is becoming the king of all-base dS-8201 leading the innovation breakthrough

In early June 2020, the ASCO conference was concluded, and the author gave a preliminary introduction to the important progress of tumor immunity under lung cancer indication in this session, in which the first disclosure of THE TIGIT monoanti-tiragolumab clinical data has attracted much attentionThis paper hopes to summarize several drugs that deserve attention under the gene mutation lung cancerSince 1997, the world's first EGFR inhibitor has launched clinical trials, and for more than 20 years, 1Targeted therapies such as EGFR, ALK, ROS1, etcare emerging, which benefits patients with non-small cell lung cancer with different fine stratifications; RET, c-MET, etcare also emerging as a new targeted chemotherapy program, which is also improving the survival of specific lung cancer patients; A new generation of targeted chemotherapy programs is also improving the quality of life of patients with drug-resistant mutations; The identification of new targeted gene mutations determines the basis for future targeted chemotherapy breakthroughsDOI: IOhitini: A rising non-small cell lung cancer full-base hit king November 13, 2015, the first EGFR T790M mutation-targeted chemotherapy program Terisha (Ohitini) was approved in the United States, the next generation of targeted chemotherapy program in improving the quality of life of patients with drug-resistant mutations, this is a milestone progress! Teresa has leapt to standard therapy for patients with Stage IV EGFR/EGFR T790M mutationsOn November 13, 2015, Teresa (Ohitini) was approved for the first time worldwide, and is currently approved in 46 countries around the world for the first time, the egFR T790M mutation of non-small cell lung cancer; On April 18, 2018, Teresa (Ohitini) harvested a first-line therapy, indications EGFR exon 19 del/ exon 21 L858R mutation non-small cell lung cancer patients, EGFR exon 19 del/ exon 21 The L858R mutation is the two most common in patients with non-small cell lung cancer and has been approved in 20 countries around the world; EGFR exon 20 ins patients are still breaking through, but there is little hopeTeresa is the first targeted therapy for patients with early EGFR mutations that can bring clinical benefits to patients with non-small cell lung cancer (I/II/III) which is an important development direction for the next phase of Ochtinib, which is key to determining the market value of OchitinibAt the 2020 ASCO conference, Ohitini announced a major breakthrough, with closeattention ADAURA (NCT02511106) data showing ositini (NCT02511106) data showing that placebo can significantly prolong disease-free survival in patients with phase II/IIIa non-small cell lung cancer, 2 years DFS 90% vs34%, HR 0.17ADAURA Pilot Program: Astra Zeneca, ASCO 2020ADAURA significantly extended disease-free survival of patients with disease-free patients AstraZeneca, ASCO 2020ADAURA significantly extended the disease-free survival of Patients with Ib/II/IIIa patients AstraZeneca, ASCO 2020 Terisa is growing into a non-small cell lung cancer whole-base fighting king ADAURA success is an important breakthrough, Oshini's first to become an early-stage clinical outcome for patients with an early-stage ADAURA will significantly expand ochedini's clinical beneficiaries, and Ohitini's path to grand io-upgrade is getting worseIn the future, Ohitini's direction to watch: 1In patients with stage IV EGFR/EGFR T790M mutations, Ochitinib is expanding combination therapies to continue to expand patientclinical benefits; I/II/III Non-Small Cell Lung Cancer Patient Assisted/New Assisted Therapy, Ositini is expanding the beneficiary population, ADAURA, NeoADAURA, LAURA is a very interesting 3 clinical trialsAstra Zeneca, IINon-small cell lung cancer stratification: c-MET-driven gene mutation patients precision therapy in the mid-1980s, mesenchymal epithelial transition factor (MET, c-Met) for the first time found that 1990s found a link between c-Met mutation and lung cancer, and in subsequent gradually clarified c-Met gene rearrangement, amplification, mutation and upward expression of the clinical benefit of lung cancer patients In general, there are 3 common forms of HGF/c-MET signal path abnormality: 1 c-MET rearrangement (rearrangement), activation mutation (mutation) and gene amplification (amplification); Increased expression of c-MET protein (overexpression); 3 The ligand-dependent c-MET protein continued to activate, and the data showed that c-MET amplification was closely associated with eGFR inhibitor resistance, with about 3% of non-small cell lung cancer patients having a jump mutation of 14 exons and about 2% of gene amplification On March 25, 2020, The world's first c-Met selective inhibitor, Tepmetko ® (Tepotinib), was approved for the first non-small cell lung cancer in Japan with the first jumping mutation of MET 14 exnophrin AsCO also updated tepotinib data (#9556) in 2020, but this is not the focus of this article, and interested patients can view official data in detail Sym015 in MET amp/exon 14 del non-small cell lung cancer patients have good response: ORR 25% Symphogen, ASCO 2020Sym015-01 Clinical trial design Symphogen, ASCO 2020Sym015 with good clinical response, 20 patients, 5 cases (25%) Response to Symphogen, ASCO 2020Sym015 is composed of two humanized IgG1 monoclonal antibodies, Hu9006, Hu9338, that target different epitopes of MET Sym015 can avoid off-target and acquired drug resistance to some extent, and the drug can further enhance the clinical benefits of patients Sym015 is a MET targeted therapy of concern in addition to Tepotinib Three Non-small cell lung cancer stratification: HER2-driven gene mutation patients ushered in breakthrough therapy May 18, 2020, DESTINY-Lung01 data show that traszumatub deruxtecan can bring significant clinical benefits to patients with advanced metastatic platinum chemotherapy progression OF HER2 mutation non-small cell lung cancer patients, FDA awarded its breakthrough therapy recognition Trastuzumab deruxtecan: Breast cancer, stomach cancer, non-small cell lung cancer innovative choice On December 20, 2019, trastuzumab deruxtecan was approved for 3-line treatment for HER2-positive breast cancer patients, which is the first in the world, the drug's heavy road officially opened, innovation breakthrough has not stalled! Daiichi Sankyo, Breakthrough Therapy: Trastuzumab deruxtecan provides excellent clinical response to PATIENTs with HER2 mutant non-small cell lung cancer Daiichi Sankyo, deruxtecan: Super-heavy bomb start-up Trastuzumab deruxtecan is expected to be the first approved targeted therapy for patients with HER2 mutant non-small cell lung cancer, with statistics showing that the ratio of HER2/3 abnormal patients with lung scale cancer and lung cancer is 2-4 Four Patients with lung cancer resistance mutations: amivantamab performed well in Oxitinib patients with early response amivantamab (EGFRxcMET DuoBody®) is an EGFR/c-Met bispecific antibody developed by Genmab, amivantamab is a drug of concern to EG mutant FR patients At the 2020 ASCO meeting, amivantamab updated early response data for patients with EGFR exon20 int mutation, 39 out of 50 patients were assessable, 14 were PR, and the objective mitigation rate was 36% NCT02609776 is still in progress, and the benefits of amivantamab in patients with various mutations in the EGFR-driven gene are still being assessed Five Targeted treatment options: Non-small cell lung cancer patients benefit from the gradual improvement of the IASLC lung cancer staging project: proposals for the tNM stage groupings in the "the forthcoming" (eighth) edition of the TNM for class for class lung cancer, tumor immunity has been driven gene mutation advanced non-small cell lung cancer patients survival significantly extended, targeted chemotherapy is also providing clinical benefits to the patients with the gene mutation clinical benefit EGFR targeted therapy, EGFR exon 20 ins non-small cell lung cancer patients will usher in a new approach, such as mobocertinib, double anti-amivantamab; 2 KRAS targeted therapy, KRAS G12C mutation non-small cell lung cancer patients will also have new breakthroughs, such as sotorasib; New targeted therapy is expanding and accurately tapping into the beneficiary population, while the new generation of targeted therapy represented by Ochtinib is revolutionizing the clinical benefits of patients with drug-resistant mutations, such as Ochtinib and amivantamab.